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Abstract 
Adult skeletal tissue is composed of heterogeneous population of cells that constantly self‑renew by means of a 
controlled process of activation and proliferation of tissue‑resident stem cells named satellite cells. Many growth fac‑
tors, cytokines and myokines produced by skeletal muscle cells play critical roles in local regulation of the inflamma‑
tory process and skeletal muscle regeneration during different pathological conditions. IL‑6 is a pleiotropic cytokine 
released in large amount during infection, autoimmunity and cancer. Low levels of IL‑6 can promote activation of 
satellite cells and myotube regeneration while chronically elevated production promote skeletal muscle wasting. 
These distinct effects may be explained by a crosstalk of the IL‑6/IL‑6 receptor and gp130 trans‑signaling pathway 
that oppose to regenerative and anti‑inflammatory of the classical IL‑6 receptor signaling pathway. Here we discuss 
on potential therapeutic strategies using monoclonal antibodies to IL‑6R for the treatment of skeletal muscle wasting 
and cachexia. We also highlight on the IL‑6/JAK/STAT and FGF/p38αβ MAPK signaling pathways in satellite cell activa‑
tion and the use of protein kinase inhibitors for tailoring and optimizing satellite cell proliferation during the skeletal 
muscle renewal. Future investigations on the roles of the IL‑6 classical and trans‑signaling pathways in both immune 
and non‑immune cells in skeletal muscle tissue will provide new basis for therapeutic approaches to reverse atrophy 
and degeneration of skeletal muscles in cancer and inflammatory diseases.
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Background
Interleukin (IL)-6 is one of hundreds cytokines, chemokines 
and growth factors that function as mediators of the innate 
and adaptive immune responses (Pal et  al. 2014; Hunter 
and Jones 2015). In addition, IL-6 exerts endocrine and 
metabolic functions on various organs including liver, fat, 
gut, pancreas and skeletal muscle. Recent studies have 
revealed the pivotal role of IL-6 during exercise-induced 
skeletal muscle injury and repair (Pedersen 2000; Benatti 
and Pedersen 2014). Nonetheless, under some pathologi-
cal conditions, IL-6 leads to muscular atrophy (Tsujinaka 
et al. 1996; Baltgalvis et al. 2008). Acting at skeletal muscle 
tissue IL-6 may promote the proliferation of satellite cells 
and their incorporation as new myonuclei into existing 
fiber syncytia (Cantini et al. 1995). Although the direct link 
between these phenomena has not fully established in vivo, 
exercise and anti-IL-6 receptor based approaches have now 
been considered as valuable therapeutic strategies to com-
bat muscle wasting associated with chronic inflammatory 
conditions (Ardies 2002; Narsale and Carson 2014). Here 
we will review emerging concepts and mechanisms that 
underlie the complex biology of IL-6 in regard to its roles in 
cancer cachexia and skeletal muscle renewal. Finally we will 
outline the benefits and side effects that therapy with mon-
oclonal antibody to IL-6 and IL-6R may bring to patients 
undergoing skeletal muscle wasting.
Satellite cells and skeletal muscle renewal
Skeletal muscle is a very dynamic and heterogeneous 
tissue of adult human body (Bassel-Duby and Olson 
2006; Bentzinger et al. 2012). Striated muscle represents 
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approximately 40 % of total body weight and plays diverse 
roles in the whole-body metabolism (Bassel-Duby and 
Olson 2006; Muscaritoli et  al. 2010). This tissue is con-
sidered an endocrine organ as it produces and secretes 
growth factors, cytokines and peptides, referred to as 
myokines (Pedersen and Febbraio 2012). Many myokines 
have been described by their ability to exert positive 
and negative effects on the skeletal muscle self-renewal 
(Muñoz-Cánoves et al. 2013; Pal et al. 2014).
Adult skeletal muscle fibers consist of multinucle-
ated differentiated myocytes that adapt to physiologi-
cal demands imposed by body growth, physical training 
and trauma. Damaged skeletal muscle are repaired and 
replaced (Yablonka-Reuveni et  al. 2008). The ability to 
repair and maintain skeletal muscle is attributed to satel-
lite cells, the muscle-resident myogenic stem cells which 
are formed during embryonic development and sit at sat-
ellite position outside the myofiber under the basal lam-
ina and account for approximately 5  % of the cell mass 
in adult skeletal muscle (Bentzinger et al. 2012; Yin et al. 
2013; Chang and Rudnicki 2014).
Satellite cell populations are comprised of satellite stem 
cells and satellite myogenic cells; each population is char-
acterized by a set of distinct markers (Yin et  al. 2013; 
Motorashi and Assakura 2014). In adult skeletal mus-
cle, most of satellite cell populations express the paired 
domain transcription factors Pax7 and Pax3, and myo-
genic regulatory factors MyoD and MyF5 in the nucleus. 
They also express at the membrane the proteins: caveo-
lin-1, cell surface attachment receptor intergin α7, trans-
membrane heparan sulfate proteoglycans: syndecan-3 
and -4, cluster of differentiation protein 34 (CD34) and 
the calcitonin receptor, which can vary at some point 
during the development across multiple species (Seale 
and Rudnicki 2000; Seale et  al. 2000; Yin et  al. 2013). 
Figure 1 shows an immunohistochemical assay for iden-
tification of satellite cells in human vastus lateralis mus-
cle. The satellite cells are identified as Pax7 positive cells 
with nuclei stained blue with Hoescht 33342. They are 
located within the basal lamina as revealed by laminin 
expression. Further details are described in Brooks et al. 
(2010). These and other biomarkers contribute intrinsi-
cally to different properties of satellite cells depending 
on their origin (Brooks et al. 2010; Yin et al. 2013). The 
basic helix-loop-helix family of muscle regulatory tran-
scription factors (MRF): Myf5, Myf6, Myod1 (MyoD) 
and myogenin play key roles in satellite cell commitment 
for myotube formation (Kollias and McDermott 2008; 
Chang and Rudnicki 2014). MyoD and Myf5 are activated 
by Pax7 which is mainly expressed in quiescent satellite 
cells and is co-expressed with MyoD during myoblast 
proliferation, but declines during differentiation due to 
activation of myogenin (Elia et al. 2007).
In adulthood, satellite stem cells remain in quiescent 
state and are activated in response to specific signals 
that promote their exit from the basal lamina. Satellite 
cell activation causes their symetric and asymmetric cell 
division, which produce stem and committed progenitors 
(Seale and Rudnicki 2000; Shi and Garry 2006; Motorashi 
and Assakura 2014). Once properly stimulated, these 
cells proliferate, differentiate and fuse into new or exist-
ing myotubes, thereby facilitating skeletal muscle repair 
or overgrowth (Yablonka-Reuveni et  al. 2008). Satellite 
cells are located at specific niches of skeletal muscle tis-
sue where specific chemical microenvironment exists 
to maintain their quiescence and undifferentiated state 
(Boonen and Post 2008; Yin et al. 2013). Changes in this 
microenvironment, in response to physiological and/
or pathological stimuli, allow escape from the quiescent 
state, and initiation of activation and differentiation pro-
cesses into myotubes (Gopinath and Rando 2008). Dis-
ruption of proliferative capacity and reduced quiescent 
cells populations are linked to aging and muscle dystro-
phies (Carlson and Conboy 2007; Brien et al. 2013). Loss 
of regenerative capacity in skeletal muscles is caused 
by excessive cycles of degeneration, regeneration and 
increased interstitial fibrosis. One study elegantly dem-
onstrated that satellite cells are essential for skeletal mus-
cle regeneration using mdx mouse model as surrogate 
of Duchenne muscular dystrophy, which is caused by a 
point-mutation in dystrophin gene (Luz et al. 2002).
The contribution of endogenous satellite cells to mus-
cle regeneration has clearly been demonstrated using the 
Cre-lox system in mice as this approach allows sophis-
ticated temporal control of pax3, pax7, myf5 and myoD 
gene expression and/or deletion (Relaix and Zammit 2012; 
Yin et al. 2013). Myod1−/− mutant mice display markedly 
reduced musculature due impaired skeletal muscle cell 
differentiation (Megeney et al. 1996). In contract, Myf5−/− 
mutant mice display myofiber hypertrophy and impair-
ment in the myoblast proliferation (Gayraud-Morel et  al. 
2007). The inactivation of both Myod1 and Myf5 genes in 
double knockout transgenic mice results in complete loss 
of formation of skeletal muscle (Gayraud-Morel et al. 2007; 
Bryson-Richardson and Currie 2008). Recently, experi-
ments using a parabiotic pair of young and old mice have 
suggested that factors present in the circulation of young 
mice are capable of inducing the rejuvenating activity and 
muscle repair in aged mice (Blau et  al. 2015). GDF11, a 
transforming growth factor beta (TGF-β) superfamily 
member, is a putative systemic rejuvenation factor (Blau 
et  al. 2015). These studies have been a matter of intense 
debate in the literature (Brack and Muñoz-Cánoves 2016).
Several family of growth factors including Shh (sonic 
hedgehog embryonic factor), Noggin, fibroblast growth 
factor family member (FGFs) and transforming growth 
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factor-beta family members (TGF-β) are required for 
proliferation and differentiation of skeletal muscle satel-
lite cells into myotubes (Parker et al. 2003; Zammit et al. 
2006). Shh binds to the receptor PTCH1 (Patched1) and 
activates protein Smo (Smoothened). Smo induces the 
activation of the transcription factor Gli, which trans-
locate to the nucleus, increasing the transcription of 
MRFs, which control the activation of muscle differ-
entiation-specific genes, including Myf5 (Halevy et  al. 
1996; Riobo et al. 2006; Bryson-Richardson and, Straface 
et  al. 2009). Even though Shh signaling pathway does 
not appear to be activated in postnatal life, it was dem-
onstrated that this pathway can be reactivated during 
skeletal muscle ischemia and infarction (Kusano et  al. 
2005). FGFs have multiple isoforms which participate in 
the proliferation of activated satellite cells via the Ras–
Raf–MEK–ERK signaling pathway (Shi and Garry 2006; 
Carlson and Conboy 2007). The activation of both p38α 
and p38β mitogen-activated kinase pathway is required 
to progression of embryonic progenitor cells into the 
myogenic program (Shi and Garry 2006; Carlson and 
Conboy 2007).
During skeletal muscle inflammatory process, 
immune cells, in particular, neutrophils, eosinophils and 
macrophages produce many growth factors; cytokines, 
lipids mediators, as well as damage-associated molecu-
lar patterns released by death cells, have a great impact 
on satellite cell behavior and the skeletal muscle repair 
process (Kharraz et al. 2013). Interleukin (IL)-6 is one of 
important mediator that play a pivotal role in the regen-
erative and anti-inflammatory processes (Cantini et  al. 
1995).
Interleukin‑6
IL-6 is secreted as glycoprotein of 21–28  kDa by both 
lymphoid and non-lymphoid cells and participate in 
many leukocyte functions, hematopoiesis and acute 
phase reactions (Pal et al. 2014; Hunter and Jones 2015). 
IL-6 belongs to the granulocyte colony-stimulating fac-
tor-like protein family of cytokines (Pal et al. 2014). The 
superfamily of IL-6 includes IL-6 itself, IL-11, IL-27, 
IL-31, leukemia inhibitory factor (LIF), ciliary neuro-
trophic factor (CNTF), oncostatin M (OSM), cardiotro-
pin-1 (CT-1), neuropoietin (NPN) and cardiotropin-like 
Fig. 1 Immunohistochemical identification of satellite cells and myonuclei in human vastus lateralis muscle. Satellite cells are distinguished using 
co‑staining for Pax7, laminin and DNA. Panels are images of a representative cross‑section of skeletal muscle tissue stained for: Pax7 (a), myonuclei 
with Hoescht 33342 (b), laminin (c) and the merge image (d). Adapted from Brooks et al. 2010
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cytokine (CLC) (Lahiri et  al. 2001; Skiniotis et  al. 2008; 
Chalaris et al. 2011). These cytokines and growth factors 
bind to specific receptors and activate a series of target 
genes involved in cell proliferation, cell differentiation, 
apoptosis and pro- and anti-inflammatory biochemi-
cal processes. The glycoprotein 130 (gp130 or CD130), 
a membrane-bound co-receptor is the major member of 
the family of ‘‘tall’’ cytokine receptors which homodimer-
ize or heterodimerize with several receptors in the family 
performing a central role in the activation of intracellular 
signaling pathways (Heinrich et  al. 2003; Skiniotis et  al. 
2008; Pal et  al. 2014; Wolf et  al. 2014). The structural 
model and the architecture of the homo- and heterodi-
mer complexes and multiple contact sites within recep-
tors and gp130 are presented and discussed in detail 
elsewhere (Skiniotis et al. 2008).
IL-6 exerts its biological activities through two mol-
ecules: IL-6 receptor alpha (IL-6Rα or CD126) and gp130 
(Fig. 2). The classical IL-6Rα activation is initiated upon 
binding of IL-6 to the two membrane-bound p80 recep-
tors that is followed by recruitment and homodimeri-
zation of the gp130. The hexameric complex cause the 
phosphorylation of gp130 intracellular tyrosine resi-
dues and transcription factors STAT (signal transducer 
and activators of transcription) by Janus kinases JAK1, 
JAK2, TYK2 (Heinrich et al. 2003; Matsushita et al. 2005; 
Hunter and Jones 2015). STATs translocate into nucleus 
and bind to DNA promoters of target genes. The IL-6R/
gp130 receptor complex also leads to activation and the 
Ras-Raf-ERK (extracellular signal regulated kinase)/
MAPK (mitogen-activated protein kinase) pathway and 
the PI3K (phosphoinositide 3-kinase) and the serine/
threonine protein kinase B/Akt pathway (Pedersen et al. 
2001; Kallen 2002). The net biological activity of IL-6 
depends on the formation of a particular functional 
receptor complexes and a variety of downstream bio-
chemical regulatory events. Three families of regulators 
of JAK/STAT signaling are known: the SOCS (suppressor 
of cytokine signaling) family, the PIAS (protein inhibi-
tor of activated STAT) family and the SHP2-containing 
phosphatase family, which are proteins that interact with 
distinct downstream effectors (Heinrich et al. 2003; Mat-
sushita et al. 2005). SOCS3 is a classical feedback inhibi-
tor of STAT3 activation involved in signaling pathways 
that determine the synthesis of a wide range of target 
genes in liver and skeletal muscle (Skiniotis et al. 2008).
The expression of IL-6R gene is restricted to some cell 
types; however IL-6 can act on a large range of cells and 
tissues (Mullberg et al. 2000; Kallen 2002). The ubiquitous 
activity of IL-6 is explained by the unrestricted expres-
sion of gp130 on many cell types that do not express 
membrane-bound IL-6R (Mullberg et  al. 2000; Kallen 
2002; Scheller et  al. 2006; Fasnacht and Muller 2008; 
Schellera et al. 2011). According to data of many studies, 
IL-6 interacts with soluble IL-6R and this complex asso-
ciated with the membrane-bound gp130 triggering JAK/
STAT pathway (Kallen 2002; Scheller et  al. 2006; Schel-
lera et al. 2011). This mechanism of transmission is called 
trans-signaling (Fig. 1). IL-6R molecules are shedding of 
membrane bound IL-6Ra after cleavage by metallopepti-
dases ADAM-10 and -17. In cells that weakly express or 
do not express IL-6R, such as hematopoietic stem cells, 
neural cells and smooth muscles, trans-signaling is criti-
cal for IL-6 activity (Mullberg et al. 2000; Schellera et al. 
2011). Although soluble receptors typically inhibit ligand 
activity by functioning as decoy moieties, sIL-6R itself 
promotes IL-6 activity. For example, sIL-6R inhibits car-
diomyocyte apoptosis in a mouse model of myocardial 
infarction (Matsushita et al. 2005). 
Regulation of IL-6 biological activities goes beyond 
soluble IL-6Rα. Complex IL-6/sIL-6R can engage mem-
brane-bound gp130 but also its soluble form (sgp130) 
that in turn acts as a decoy receptor (Scheller et al. 2006; 
Schellera et  al. 2011). The membrane IL-6R and gp130 
levels can dictate whether sIL-6R acts as agonist or 
antagonist. For cells with comparable IL-6R and gp130 
levels, IL-6 activity is not inhibited by sIL-6R. In cells that 
IL-6R is highly expressed than gp130, the addition of sIL-
6R, inhibit the response to IL-6 because of the formation 
of an inactive complex containing only one molecule of 
gp130 (Scheller et al. 2006).
Exercise increases IL‑6 synthesis by skeletal muscle 
cells
Exercise is a complex process involving the synchronized 
and integrated activation of multiple tissues and organs, 
in particular, musculature, at the cellular and systemic 
level (Hawley et  al. 2014). Following progressive exer-
cise training, skeletal muscle mass is increased due to net 
gain in protein synthesis (Russell 2010). Regular physical 
exercise has a protective effect against various diseases 
such as cardiovascular diseases and obesity. Moreover, 
it increases life span and retards appearance of illness 
in elderly (Pedersen 2000, 2011; Ardies 2002). Regular 
exercise and physical activity is associated with specific 
production of cytokines and myokines, including IL-1β 
(Cannon et al. 1986), IL-6, TNF-α, TNF receptors, IL-10, 
IL-8, IL-1 receptor antagonist and acute phase proteins 
(Pedersen 2000; Febbraio and Pedersen 2002) by the skel-
etal muscle to maintain the metabolic homeostasis of 
lipids and proteins. Many studies have reported on the 
biological effects exerted by myokines to increase the 
energy supply including glucose uptake via translocation 
of GLUT4 (Weigert et al. 2006); as well as to increase the 
synthesis of glycogen (van Hall et  al. 2003) and hepatic 
production of glucose and its absorption by the intestine 
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epithelial cells (Pedersen et  al. 2001; Egan and Zierath 
2013).
IL-6 mediates many aspects of the exercise-induced 
acute-phase response, including the up regulation of 
antioxidant defenses as response to oxidative stress 
(Sacheck et  al. 2008). After strenuous physical exer-
cise, IL-6 is synthetized by actively contracting muscle 
fibers and increase up to 100-fold in relation to other 
pro-inflammatory cytokines such as TNF-α and IL-1β 
(Pedersen 2000; Pedersen et  al. 2004; Benatti and Ped-
ersen 2014). It has been proposed that IL-6 and other 
myokines produced in response to strenuous and pro-
longed exercise lead to increased proliferation of satellite 
cells and thereby regeneration of damaged myofibers 
(Cantini et al. 1995; Steensberg et al. 2001). Serrano et al. 
demonstrated that muscle hypertrophy under the action 
of IL-6 requires STAT3 activation (Serrano et  al. 2008). 
This study showed a clear evidence for the contribution 
of satellite cells using mice lacking IL-6 gene in skeletal 
muscle (Serrano et  al. 2008). STAT3 play a critical role 
during development and its deletion lead to early embry-
onic lethality (Takeda et al. 1997). STAT3 has been exam-
ined a possible target for skeletal muscle repair since it is 
critical for MyoD1 mediated transcription of myogenesis 
genes (Tierney et al. 2014). It was observed that only one 













Fig. 2 IL‑6 classical and trans‑signaling pathways. a IL‑6 binds to cells that express both the membrane bound IL‑6R gp130 and trigger the activa‑
tion of the JAK/STAT signaling pathway. This type of signaling is called classical signaling. b In cells that express only gp130 but not IL‑6R, IL‑6 binds 
to soluble IL‑6R (sIL‑6R) and the complex in turn bind to gp130 to trigger the activation of intracellular signaling. This type of signaling is called 
trans‑signaling. The sIL‑6R is released by proteolytic cleavage of the IL‑6R membrane bound precursor by the metalloproteases ADAM10 and 17. A 
natural form of gp130 is able to bind to the sIL‑6R bound to IL‑6 with comparable affinity and mediates inhibition of IL‑6 trans‑signaling
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Fig. 3 Skeletal muscle morphological alterations in cancer cachexia revealed by confocal (a–d) and transmitted electron (e, f) microscopic exami‑
nation of a cross section of soleus muscle from mouse bearing B16 melanoma and severe cachexia as compared to normal soleus obtained from 
control C57BL/6 mouse. Myocyte apoptotic cell death is characterized by DNA fragmentation and deposition of chromatin masses around nuclear 
membrane. In a, a representative image illustrating the normal flattened nuclei located in parallel with skeletal muscle fibers in the periphery of 
normal myotube. In b, the image shows irregular nucleus with visible clumping of nuclear chromatin confirming cell death by apoptosis. In c, the 
micrograph shows the myosin banding displaying regular cross‑striations and intense fluorescence. In d, illustrates myosin appearance in cachec‑
tic skeletal muscle fiber. The weak fluorescence intensity is reflecting breakdown of myofibril and tissue architecture. Nuclei were stained with 
propidium iodide and myosin pattern was revealed with monoclonal antibody to fast myosin skeletal heavy chain (lower panel). In e, the electron 
micrograph shows a nucleus with normal morphology (upper side) and a typical apoptotic nucleus with condensed chromatin fragments at its 
periphery (lower side). In f, the micrograph shows a portion of sarcolemma surrounded by mitochondria and vacuoles containing apoptotic bodies 
(autophagosome). The ubiquitin–proteasome and autophagy‑lysosome pathways are the two major routes for protein and organelle degradation 
along skeletal muscle wasting
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aged, injured or dystrophic skeletal muscles can promote 
myofiber repair. One explanation for the positive results 
is that partial STAT3 inhibition, by augmenting repeated 
rounds of satellite cell expansion, may prevent the 
exhaustion of reservoir of the muscle satellite cells (Tier-
ney et al. 2014). This mechanism need to be explored in 
response to long term training. It is interesting that the 
skeletal muscle tissue of mice genetically deficient of 
myostatin gene (Mstn−/−) retains the same metabolic 
plasticity and adapted normally to endurance training 
(Savage and McPherron 2010). This is consistent with 
the results of recent study showing that muscle satellite 
cells do not play any role in skeletal muscle hypertrophy 
induced by inhibition of the myostatin/activin signal-
ing pathway or deletion of Acvr2b gene which encodes 
a high-affinity receptor for myostatin and activin A (Lee 
et al. 2012).
IL‑6 induces muscle wasting and cancer cachexia
The development of neoplastic disorders is linked to 
biochemical changes in the body, which include reduc-
tion of the nutrient intake of nutrients and stimula-
tion of catabolic pathways, and ultimately to the onset 
of cachexia (Baracos and Mackenzie 2006; Fearon et  al. 
2011). Cachexia is defined as a multi-factorial syndrome 
(Evans et al. 2008; Argiles et al. 2010). This syndrome is 
present in patients with cancer and various chronic dis-
eases among them, AIDS, diabetes, kidney failure and 
heart failure (Rubin 2003; Tan and Fearon 2008; Muscari-
toli et al. 2010). Cachexia accounting for 20–50 % of the 
deaths of these patients (Tan et al. 2008; Muscaritoli et al. 
2010; Fearon et al. 2011). Cachexia reduces the patient’s 
response to chemotherapy and radiotherapy (Laine et al. 
2013), and the weight loss is inversely proportional to 
survival time and directly related to worse prognosis 
and poor quality of life of patients (Fearon 2008; Tan and 
Fearon 2008; Fearon et al. 2011; Laine et al. 2013; Argiles 
et al. 2014a).
Skeletal muscle morphological alterations in cancer 
cachexia (see Fig.  3 as example) have been attributed 
to many factors and mechanisms depend on cancer 
cell type, animal model and the experimental protocol. 
Cachexia promotes a drastic reduction of body weight 
due to inhibition of protein synthesis and increased 
degradation, especially, of skeletal muscle proteins 
(Inui 1999; Ventrucci et al. 2002; Schiaffino et al. 2013). 
Several hormones, growth factors, pro-inflammatory 
cytokines and humoral factors have been described as 
potential mediators of muscle mass loss (Tisdale 2004; 
Fearon et  al. 2012; Argiles et  al. 2014b). There is strong 
evidence that cachexia in patients with cancer involves an 
inflammatory process with an increased release of pro-
inflammatory and anti-inflammatory cytokines (Argiles 
et al. 2005; Seelaender et al. 2012). The presence of these 
cytokines leads to anorexia, weight loss, changes in the 
metabolism of lipids and proteins, increased concentra-
tions of catabolic hormones, reduction of anabolic hor-
mones and metabolic impairment (Rubin 2003; Argiles 
et al. 2005; Seelaender et al. 2012). In fact, several studies 
have shown that TNF-α, IL-1, IL-6 and interferon gamma 
(IFN-γ), released by both tumor cells and the host in 
response to the tumor may lead to activation of differ-
ent pathways of intracellular protein degradation (Tisdale 
2004, 2009). Cachetin/TNF-α was the first cytokine iden-
tified that was able to reproduce most of the symptoms 
of cachexia in mice including changes in protein turnover 
and increased protein degradation (Oliff et al. 1987; Fong 
et al. 1989). IL-1α and β also contribute to protein deg-
radation in rats and their administration also promoted 
weight loss and anorexia (Belizario et  al. 1991; Shibata 
et  al. 2000). It is interesting that the presence of IL-1β 
gene allele contributed to the occurrence of cachexia 
associated with gastric cancer in the Chinese population 
(Zhang et al. 2007).
IL-6 is capable of induce cachexia altering the metabo-
lism of lipids and proteins as well as impairing myogenic 
differentiation in certain types of cancer (Jablons et  al. 
1989; Holmer et al. 2014; Narsale and Carson 2014; Pelosi 
et  al. 2014). Studies undertaken with IL-6 transgenic 
mice and colon-26 tumor-bearing mice that display ele-
vated plasma IL-6 levels have demonstrated about 25 % 
decrease in gastrocnemius muscle weight (Zhou et  al. 
2003). In patients with cancer cachexia, high circulating 
levels of IL-6 seems to act as mediator of skeletal muscle 
proteolysis (Tsujinaka et al. 1995). In fact, the overexpres-
sion of IL-6 in transgenic mice caused muscular atrophy 
and increased levels of cathepsin in skeletal muscle, indi-
cating that IL-6 is involved in the regulation of muscle 
protein degradation (Tsujinaka et al. 1996). Haddad et al. 
(2005) showed that infusion of IL-6 causes muscle atro-
phy by a mechanism involving the reduction in phospho-
rylation of ribosomal protein kinase S6K1 and increased 
transcription of SOCS-3. Kwak et al. (2004) showed that 
in undifferentiated C2C12 myoblasts the treatment with 
IL-6 stimulates protein ubiquitination mainly by increas-
ing the activity of ubiquitin ligase E3 α-II, suggesting 
that this cytokine contributes to the development of the 
process of cachexia. Recently, another study showed 
that IL-6 induces protein loss activating the JAK/STAT 
signaling pathway (Baltgalvis et  al. 2009). Nonetheless, 
some authors consider that IL-6 act together with other 
cytokines thus has only a permissive role in the develop-
ment of skeletal muscle proteolysis.
The TGFβ-superfamily members, including TGF-β1, 
GDF-8 (myostatin), GDF-11, GDF-15, activin A and B, 
nodal, BMP-2 and BMP-7 are well known by their role 
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in the induction of muscle atrophy (Kollias and McDer-
mott 2008; Glass 2010a, b). Myostatin (Mstn) inhibits 
differentiation of myoblasts via the Akt/mTOR pathway 
which promote inhibition of MyoD and myogenin syn-
thesis (Glass 2010a, b). In several farm animals, mutation 
or deletion of Mstn gene increased 2–3 times skeletal 
muscle mass as compared to wild-type animals, thus 
highlighting its role in regulating hypertrophy and hyper-
plasia programs in the skeletal musculature (McPherron 
et  al. 1997). Myostatin, upon binding to type II activin 
receptors (ACVR2 and ACVR2B), form a complex with 
a type I receptor, either activin receptor-like kinase 4 
(ALK4) or ALK5, to stimulate the phosphorylation of the 
Smad2 and Smad3 transcription factors (Glass 2010a, 
b). ACVR2B is a high affinity activin type 2 receptor that 
mediates the intracellular signaling induced by myosta-
tin, activin and GDF11 in skeletal tissue, whose inhibition 
attenuate cancer cachexia (Zhou et al. 2010). The block-
ade of ACVR2B through a direct neutralizing antibody 
has been approved for the treatment of multiple condi-
tions associated with muscle wasting (Lach-Trifilieff et al. 
2014). Insulin-like growth factor (IGF1) can counteract 
myostatin’s effects by rescuing of the PI3K/Akt pathway. 
It is interesting that ACVR2B inhibition also results in 
restoration of PI3K/Akt signaling (Lach-Trifilieff et  al. 
2014). Recently myostatin was identified in the secretome 
of C26 colon cancer cells and experimentally confirmed 
as novel tumoral factor that induces cancer cachexia via 
binding to ACVR2B (Lokireddy et al. 2012).
Many intracellular protein degradation systems are 
activated during skeletal muscle atrophy (Goldberg 
2003). The ATP-ubiquitin–proteasome pathway play a 
principal role (Goldberg 2003; Lecker et al. 2006; Pickart 
and Cohen 2004). In this way, proteins are first marked 
for degradation by a covalent addition of an ubiquitin 
chain (known as multi-ubiquitination). This lead to a cas-
cade of reactions that requires enzyme E1 (Ub activating), 
E2 enzymes (conjugated) and E3 (ligases) (Ciechanover 
2003; Lecker et al. 2006). Several studies have shown that 
specific groups of genes involved in ubiquitin–proteas-
ome system are induced during the loss of skeletal muscle 
in several models of cachexia and muscle atrophy (Lecker 
et al. 2004; Kandarian and Jackman 2006). The two tran-
scription factors of FoxO family: FoxO1 and FoxO3 have 
been described as the main initiator of the transcription 
of genes involved in protein degradation during muscle 
atrophy (Sandri et  al. 2004). FoxO1 and 3 participate in 
the activation of transcription of two E3 ligase genes: 
MuRF1 and MAFbx, which are selectively upregulated 
in skeletal and heart muscles (Bodine et al. 2001; Gomes 
et  al. 2001). Myostatin induced skeletal muscle wasting 
through up-regulation of FoxO1 and MuRF1 (Lokireddy 
et  al. 2012). MuRF1 binds to a large sarcomeric protein 
titin and myosin heavy chain (MyHC), thereby promot-
ing their degradation via the proteasomes (Centner et al. 
2001; Cohen et al. 2009; Lokireddy et al. 2012). However, 
ablation of MuRF1 or MAFbx only partially protects 
muscle loss during denervation (Bodine et al. 2001) and 
following glucocorticoid treatment (Baehr et  al. 2011) 
in mice indicating that other ubiquitin ligases are also 
involved in skeletal protein degradation.
The degradation of membrane receptors and long-
lived proteins during muscle atrophy is mediated by the 
lysosomal pathway in which the member of the cysteine 
family of aspartyl proteases cathepsins B, H, L and D, 
play predominant roles (Baracos et al. 1995; Costelli et al. 
2005; Mammucari and Milan 2007; Attaix and Bechet 
2007). Autophagy is a catabolic process that target dam-
aged and no longer functional cellular organelles for 
lysosomal degradation. Autophagy play essential role in 
various myopathies and in response to reduction of the 
PI3K-Akt signaling pathway induced by IGF-1 and insu-
lin (Bechet et  al. 2005; Sandri 2012). Mammucari et  al. 
(2007) and Zhao et  al. (2007) demonstrated that many 
genes involved in autophagy such as Atg (Beclin 1), LC3 
and Gabarapl1 are transcriptionally regulated by FoxO3 
(Sandri 2013). The majority of these genes are induced 
along the processes of atrophy and muscle wasting after 
fasting, renal failure, diabetes, cancer and denervation in 
different animal models (Lecker et  al. 2004; Zhao et  al. 
2007; Sandri 2013; Judge et al. 2014).
The myocyte cell death by apoptosis  (Fig. 3), which is 
mediated by caspases, also contributes to muscle wasting 
(Sandri 2002; Argiles et  al. 2005). The members of this 
family of cysteine proteases are activated by the extrinsic 
and intrinsic pathways of apoptosis (Duprez et al. 2009; 
Pop and Salvesen 2009). The inflammatory caspase-1, 
-4, -5, -11 and -12 are activated following inflamma-
some formation in response to microbe infection, cell 
stress and injury (Martinon and Tschopp 2007; Sangi-
uliano et  al. 2014). The activity of caspase-1, -3, -8 and 
-9 is increased several folds in the skeletal muscle tissue 
of mice bearing MAC16, a cachexia-inducer tumor as 
compared to non-cachexia-inducer MAC13 (Belizário 
et  al. 2001). Activation of caspase-3 is required for the 
cleavage of myofibrillar actin and possibly other myofi-
brillar and cytoplasmic proteins via the ubiquitin–pro-
teasome system (Du et  al. 2004; Wang and Mitch 2010; 
Silva et  al. 2015). Caspase-3 also cleaves specifically the 
AAA-ATPase subunits of the 19S regulatory chamber of 
the proteasome (Wang and Mitch 2010; Silva et al. 2015). 
Biochemical studies have supported the hypothesis that 
the degradation and release of 19S unit from the 26S 
large unit promote the entry of non-ubiquitinated sub-
strates into 20S catalytic chamber for their rapid degra-
dation (Takeuchi et al. 2007; Belizario et al. 2008).
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 Finally Fig. 4 depicts the interactions and cross signal-
ing events among various signaling pathways, for exam-
ple, myostatin and FOXOs, NF-κB and MURF1, and 
mTOR that are involved in myotube degradation and 
myofiber repair via myogenic satellite cells. The precise 
intersection among these pathways needs to be identi-
fied in order to determine key factors controlling atro-
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Fig. 4 Mediators and signaling pathways involved in the control of myotube degradation and repairing via satellite cell activation. a Schematic 
representation of muscle growth and muscle wasting pathways generated in the studies of gene expression patterns in skeletal muscle from cancer 
cachexia mice models. Genes with growth‑promoting activity in skeletal muscle are shown in orange and genes involved muscle wasting in green 
and genes involved in satellite cell activation in blue. This set of genes is significantly up‑regulated during food deprivation, diabetes, uremia, and 
cancer cachexia and target genes under the control of FoxO transcription factors in skeletal muscle wasting. b Quiescent satellite cells (white) acti‑
vated by myokines and injury initiate symmetric and asymmetric divisions to produce activated satellite cells (green) and self‑renewing satellite cell 
and myogenic stem cells (blue). After many rounds of division their progeny differentiate into myocytes and then myotubes. A different set of the 
transcription factors and membrane protein are expressed along each differentiation state of satellite cells. Some specific biomarkers are indicated 
in the panels inside the figure. Adapted from Bonetto et al. (2014) and Yin et al. (2013). IGF insulin‑like growth factor; INSR, insulin receptor substrate 
1; IGFR, insulin‑like growth factor receptor; PI3K, phosphoinositide 3‑kinase; GSK3, Glycogen synthase kinase 3; 4E‑BP1, Eukaryotic translation initia‑
tion factor 4E binding protein 1; mTOR, mammalian target of rapamycin; p70S6K, serine/threonine kinase; Akt, Protein kinase B; FoxO, Forkhead box 
O transcription factors; IL‑6, interleukin‑6; LIF, leukemia inhibitory factor, TNF, tumor necrosis factor, IL‑1, interleukin‑1, TRAF, TNF receptor associated 
factor; NF‑κB, factor nuclear kappa B; IKK, inhibitor of nuclear factor kappa‑B kinase; MAPK, mitogen‑activated protein kinase; JAK, janus kinase; STAT, 
Signal Transducer and Activator of Transcription; ERK, extracellular signal regulated kinase; ALK, activin receptor‑like kinase, ACVR2B, activin receptor, 
SMAD, transcription factor; Atrogin, E3 ubiquitin ligases Muscle Atrophy Fbox (MAFbx); MURF1, Muscle Ring Finger 1, MHC, myosin heavy chain; 
MCK, muscle creatine kinase; SOCS, Suppressor of cytokine signaling; BCL2/adenovirus E1B 19 kDa protein‑interacting protein 3
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and separable signaling pathways that regulate these 
molecular and cellular events are major avenues of future 
research and promise to improve multiple therapeutic 
approaches for treating skeletal muscle wasting and can-
cer cachexia.
Muscle wasting and cancer cachexia therapy
Various strategies have been studied in order to coun-
teract or prevent catabolic dysfunctions in skeletal 
muscle in preclinical and clinical trials (Argiles et  al. 
2014a). Myostatin is well known to act as an inhibitor 
of muscle mass growth (Glass 2010a, b). The pharma-
cological blockade of myostatin/activin pathway via the 
administration of an anti-myostatin monoclonal anti-
body that inhibit the binding of myostatin to its recep-
tor ActRIIB/ACVR2B was found to be the most effective 
treatment for muscle wasting in cancer cachetic patients 
(Lach-Trifilieff et  al. 2014). Nonetheless, other stud-
ies have shown beneficial effects of the blockage of IL-6 
and its signaling pathway in the control of skeletal mus-
cle wasting and cachexia progression in several mouse 
cancer models (Holmer et  al. 2014; Narsale and Carson 
2014; Pelosi et al. 2014). Fujita et al. (1996) was the first 
one to demonstrate that anti-IL-6 receptor antibody 
prevented skeletal muscle atrophy in colon-26 adeno-
carcinoma-bearing mice via modulation of lysosomal 
and ATP-ubiquitin-dependent proteolytic pathways. 
Next, Zaki and colleagues (Zaki et al. 2004) showed that 
CNTO 328 (Siltuximab), a monoclonal antibody against 
IL-6, inhibited human tumor-induced cachexia in Nude 
mice. The role of IL-6 in the onset of adipose and skeletal 
muscle wasting has been demonstrated in the in Apc-
Min/+ mouse model. This mouse strain contains a lethal 













































Fig. 5 Pharmacological approaches in pre‑clinical and clinical trials for treating inflammatory diseases and muscle wasting in cancer cachexia.  
a Chemical and biological inhibitors of IL‑6, b sIL‑6R, c IL‑6R, and d small molecule inhibitors of protein kinases, in the IL‑6R downstream signaling 
pathways. The binding of IL‑6 to IL‑6R is inhibited by monoclonal antibodies sirukumab, clazakizumab and olokizumab. The interaction of IL‑6R 
with gp130 is blocked by the monoclonal antibodies tocilizumab, sarilumab, ALD518 and siltuximab. FE999301 is a Fc‑linked sgp130 recombinant 
protein that block the interaction of the complex formed by sgp130, soluble IL‑6 and IL‑6R that act as antagonist of interleukin‑6 receptor trans‑
signaling responses. In box d are examples of small molecule inhibitors of p38α/β protein kinase activity with most highly selectivity and in box  
e are examples of phosphopeptide‑based prodrugs targeting the SH2 domain of STAT3. SHIP1, SOCS and PIAS are natural negative regulators of 
JAK/STAT signaling pathways. Abbreviations: PIAS, the protein inhibitors of activated STATs, SOCS, Suppressor of Cytokine Signaling, NF‑κB, factor 
nuclear kappa B, C/EBPβ, Enhancer Binding Protein Beta, AP‑1, Activator Protein‑1, ISRE, the IFN‑stimulatory element, GAS, the IFN‑γ‑activation site, 
and TFs, transcription factors
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intestinal adenomas (Baltgalvis et al. 2008). Of particular 
interest, it was shown that the growth of intestinal polyps 
and intestinal adenomas is associated with the increase 
in IL-6 circulating levels. Confirming these observa-
tions, Tocilizumab, a humanized anti-IL-6 receptor 
antibody, dramatically attenuated cachexia induced by 
IL-6 over-expressing lung cancer in animal model. More 
important, this data was also confirmed in a cohort of 
patients (Ando et al. 2014). The authors showed that the 
treatment reduced acute phase protein synthesis in liver 
while preserved the protein reserves in skeletal muscle of 
patients (Ando et al. 2014).
Various humanized monoclonal antibodies to IL-6 and 
IL-6R have been characterized and are in pre- and clini-
cal trials for many diseases (Fig. 5). These antibodies act 
at different structural sites of their targets and cause dif-
ferences side effects when injected in animal models 
and humans (Shaw et al. 2014; Hunter and Jones 2015). 
IL-6R trans-signaling pathway is the critical player of IL-
6-mediated pathology in autoimmune conditions such 
as rheumatoid arthritis, colitis, tissue fibrosis and cancer 
(Wolf et  al. 2014). Several clinical studies have proven 
that treatment with monoclonal antibodies to IL-6R 
improves symptoms of rheumatoid arthritis, Castleman’s 
disease and systemic juvenile idiopathic arthritis (Hunter 
and Jones 2015). The treatment causes side effects such 
as neutropenia, bacterial super-infection and disruption 
of gut mucosal integrity due to inhibition of essential 
innate and adaptive biological activities of IL-6 (Pal et al. 
2014; Hunter and Jones 2015).
Various recent studies have explored the possibility 
of inhibiting muscle wasting and catabolism interfer-
ing in the activation of intracellular signaling pathways 
using small molecules. The STAT3 activation is critically 
necessary for muscle wasting at downstream of IL-6-in-
duced cachexia in mice bearing C26 colon carcinoma, 
Lewis lung carcinoma, ApcMin/+ colon cancer and B16 
melanoma (Bonetto et al. 2012). In fact, blocking STAT3 
activation using a cell-permeable STAT3 SH2 domain 
mimetic peptide (SIP) reduced muscle wasting in mice 
undergoing cancer cachexia and sepsis (Bonetto et  al. 
2012; Silva et al. 2015). On the other hand, it is well know 
that the activation of the JAK/STAT3 downstream path-
way is necessary for satellite cell-mediated hypertrophy 
following acute muscle damage (Toth et al. 2011; Tierney 
et al. 2014). Thus, the effects of STAT3 inhibitors may be 
explained on the basis of species differences in STAT3 
activation between stem cells from mice and human ori-
gin (Hirano et al. 2000; Cornelison 2008; Toth et al. 2011; 
Do et  al. 2014). LIF and IL-6 are required as stem cell 
growth factors for embryonic stem cell lines derived from 
mouse strains (Hirano et  al. 2000). On the other hand, 
the human embryonic stem cell lines are only stimulated 
by the FGF family members, in which FGF2 is the most 
potent (Do et al. 2014).
Intracellular signals activated by FGFR1 include the 
MAPK/ERK pathway, also known as the Ras–Raf–MEK–
ERK pathway (Cuenda and Rousseau 2007). There are 
four well-characterized subfamilies of mitogen-activated 
protein kinases (MAPKs): ERK1/2, ERK5, JNKs and p38s. 
The canonical activation of p38 MAPKs occurs via dual 
phosphorylation of the p38MAPK family members: p38α 
and p38β or p38γ and p38δ (Cuenda and Rousseau 2007). 
More important, MKK3 and MKK6 (SKK3) are highly 
selective activator for p38 MAPKs and do not activate 
JNKs or ERK1/2 (Cuenda and Rousseau 2007). These pro-
teins differ in their expression patterns, substrate specifi-
cities and sensitivities to chemical inhibitors. Evidences 
from a number of studies have established a key role for 
the p38 MAPK pathway in the conversion of myoblasts 
to differentiated myotubes during myogenic progression. 
The activation of p38 mitogen-activated protein kinases 
p38α and p38β is required for satellite cell proliferation 
and asymmetric division, which produce one stem and 
one committed progenitor (Bernet et al. 2014). However, 
over activation of p38α and p38β due to cellular stress, 
inflammatory responses and ageing may result in mus-
cle atrophy due to satellite cell depletion or senescence 
(Brooks et al. 2010; Brien et al. 2013; Tierney et al. 2014). 
One critical observation in the studies of pharmacologic 
inhibition of p38α/β using small molecules is that satellite 
cells can either maintain pluripotency and self-renewal 
or entering to quiescent state depending on the dose 
and period of incubation (Brooks et al. 2010; Brien et al. 
2013; Tierney et  al. 2014). Furthermore, only recently 
very high selectivity protein kinase inhibitors to p38α 
and p38β were developed (Koeberle et al. 2012). This may 
also account for divergences observed in the experiments 
undertaken with humans and rodent models. From these 
studies, one can conclude that a major mechanism for 
muscle wasting is, on the one side, the hyperactivity of 
IL-6/JAK/STAT1/STAT3 signaling pathway that blocks 
the expression of genes, such as MyoD, MEF2 and myo-
genin, and consequently myoblast differentiation and 
fusion. And, on the other side, the impairment of FGFR1 
signaling and hyperactivity of p38α and p38β MAPK 
signaling that inhibit the proliferation of satellite cells and 
consequently skeletal muscle self-renewal.
Skeletal muscle atrophy and regrowth are regulated by 
a complex and context dependent interactions of mem-
bers of TGF-β superfamily and their receptors as well 
as extracellular matrix (ECM) protein inhibitors (Glass 
2010a, b; Lee et  al. 2010; Bonaldo and Sandri 2013; 
Blau et  al. 2015). Bimagrumab or BYM338, a human-
ized monoclonal antibody to myostatin can reverse can-
cer cachexia (Glass 2010a, b; Lach-Trifilieff et  al. 2014). 
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This antibody binds to activin type II receptors, ActRIIA 
and ActRIIB, which are primary receptors for myostatin 
(GDF8), GDF11 and activins. These receptors phospho-
rylate and activate the type I receptor ALK4 and ALK7, 
which trigger signaling transduction via Smad2 and 3 
transcription factors (Glass 2010a, b, Lach-Trifilieff et al. 
2014). GDF11 and myostatin activate the SMAD2/3, 
p38 MAPK and ERK signaling pathways via the type 
IIB activin receptor. The development of small molecule 
inhibitors to ActRII and ALK serine/threonine kinases 
would be helpful for understanding their roles in distinct 
signaling pathways. SB-431542 and SB-505124 are exam-
ples of small inhibitors that block ALK4, ALK5 and ALK7 
kinase activities in use today (Inman et al. 2002; Dacosta 
et  al. 2004). These inhibitors do not inhibit significantly 
the ERK, JNK, or p38 MAP kinases (Inman et  al. 2002; 
DaCosta et  al. 2004). It is interesting that IL-6 activate 
only STAT3 in skeletal muscle, while myostatin acti-
vate SMAD2/3 and STAT3. Therefore, future studies are 
needed to explore possible pharmacological manipula-
tion of both pathways in order to ameliorate muscle self-
renewal while stopping skeletal muscle atrophy.
Final remarks
IL-6 is a multifunctional cytokine released during inflam-
matory processes contribute not only to innate and 
adaptive immune response but also to the complex acti-
vation of metabolic and catabolic pathways leading to the 
increased liver mass and decreased skeletal muscle mass. 
The local production of IL-6 by skeletal muscle cells and 
stromal cells promotes activation of satellite cells thereby 
increasing myotube regeneration. The precise signals by 
which IL-6 orchestrates intracellular biochemical signal-
ing for skeletal muscle precursor cell proliferation and 
myotube formation remains controversial. It is possible 
that unwanted biological effects of IL-6, as that occurring 
in aging and cancer cachexia, are due to its release chron-
ically and at sustainable levels. The release at low con-
centration into satellite cell niches IL-6 would promotes 
repair and regenerates skeletal muscle tissue.
IL-6 binds IL-6Rα forming hetero-complexes with the 
gp130, which serve as a central signaling module for acti-
vation of the canonical JAK/STAT pathway. We know 
that there is an intense interaction and exchanges of 
these complexes with several different cytokines in cer-
tain pathological conditions. For example, IL-27, LIF and 
CNTF interaction with both their receptors and gp-130 
can transiently inhibit the signaling capacity of other 
family members, in particular IL-6 (Zvonic et  al. 2005; 
Skiniotis et al. 2008). Alternatively, the undesired effects 
may be explained by the degradation of the LIFR and pro-
tein gp-130 mediated by caspases and lysosomal enzymes 
(Zvonic et  al. 2005; Graf et  al. 2008). Finally, we do not 
know if IL-6 trans-signaling through the soluble IL-6R 
amplify IL-6 signaling in skeletal muscle of the cachectic 
patient. The future research to explore the both IL-6 clas-
sic signaling and trans-signaling will open new frontiers 
for design new pharmacological strategies to reverse the 
atrophy and degeneration of skeletal muscle tissue.
A myriad of factors controls intrinsic and extrinsic 
signaling pathways leading to satellite cell activation, 
and proliferation and differentiation. As highlighted in 
this review, the canonical IL-6/JAK/STAT and FGF/
p38 MAPK signaling pathways have both protective and 
detrimental effects in the skeletal muscle renewal. The 
deregulation of these signal transduction cascades in 
inflamed and atrophic muscles may be rescued by single 
specific kinase inhibitor or combination specific inhibi-
tors for different kinases (Toth et al. 2011; Tierney et al. 
2014). Therefore, further research is needed for tailor-
ing or optimizing therapeutic approaches that include 
monoclonal antibody to cytokines, growth factor and 
their receptors and small molecules inhibitors of protein 
kinase signaling pathways to treat muscle wasting and 
cancer cachexia.
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